Clinician-to-Clinician Update Clinician-to-Clinician Update

Cancer Care Specialty Updates

April 2017

— Development process for dendritic cell/myeloma fusion vaccine

Trial of dendritic cell vaccine for multiple myeloma to open

A trial testing a tumor vaccine targeting multiple myeloma will open this spring with University of Minnesota Health locations serving as one of 16 centers in the trial. The phase II trial will employ dendritic cell/myeloma fusion vaccines as part of a treatment regimen for multiple myeloma after autologous hematopoietic stem cell transplant (HCT) and will test if vaccine infusion along with granulocyte macrophage colony-stimulating factor (GM-CSF) after HCT will improve responses in patients. The fusion allows use of a broad array of patient-derived myeloma antigens presented in the context of dendritic cell-mediated co-stimulation. Eligible patients must have at least 20% plasma cells in the bone marrow for vaccine manufacture. Physicians who seek to refer patients should contact Mukta Arora, MD, MS.

Trial of maintenance regimen for high-risk multiple myeloma begins

University of Minnesota Health Cancer Care is one of 18 centers currently recruiting patients for a phase II trial that will assess maintenance with the drug ixazomib in patients being treated for high-risk multiple myeloma after allogeneic hematopoietic stem cell transplantation (HCT). Comparing progression-free survival of patients receiving the drug to those receiving a placebo after HCT, the study will test whether ixazomib maintenance therapy results in improved progression-free survival. Brian McClune, DO, is the principal investigator for the site.

NK-cell trial for myeloma announced

This spring, a phase I trial examining dosage and administration of NK cells in patients with myeloma will open. These cells, obtained from cord blood units, will be given to patients receiving a standard autologous transplant for their myeloma as part of consolidation or relapse therapy, and the trial will test correct dosage and timing of NK cell administration. Cells will then be expanded in vivo with IL-2, and patient outcomes monitored. University of Minnesota Health physician Brian McClune, DO, will serve as the local principal investigator.

For information on the trials or to refer a patient, contact the Blood and Marrow Transplant Office at 612-273-2800.

To find current clinical trials available through M Health providers:

The 2017 University of Minnesota Health Adult Specialty Directory is now available. To request a free copy, visit

Related Articles

April 2017

Novel Treatment Regimens Improve Survival Rate in Multiple Myeloma

With the help of University of Minnesota Health physicians, advances in drug development and clinical trials have established the current standard of care for patients with newly diagnosed multiple myeloma.

Continue reading

April 2017

Autologous Stem Cell Transplant Sends Patient’s Myeloma into Remission

A new treatment regimen and modified maintenance therapy help keep the patient’s multiple myeloma in complete remission 3 years after transplant.

Continue reading